Beam Therapeutics Director Carole Ho to Step Down from Board

Her departure, announced without controversy, marks a shift in the company’s leadership as it navigates 2026.

February 06, 2026

Board Change Announced

Beam Therapeutics is adjusting its leadership lineup. On January 31, the company received notice that Carole Ho will resign from its Board of Directors, effective February 27, 2026. The decision was disclosed in an SEC report filed on February 5. According to the company, her resignation wasn’t tied to any internal disagreement or policy concern.

Dr. Ho’s departure comes as Beam continues to push ahead in its development of base editing technologies. The company has a growing portfolio of gene-editing programs, and governance updates like this one matter—particularly as it navigates key milestones in clinical development and regulatory planning.

Operational Continuity

No successor has been named yet, and Beam has not shared further details beyond the filing. That said, the board transition doesn’t appear to disrupt the company’s current pace. CEO John Evans remains in place, and there were no other executive changes included in this update.

Strategic Outlook

As Beam continues to build momentum in a competitive biotech landscape, its ability to stay aligned across leadership and operations will be key. Board shifts like this are a normal part of company evolution, but they also signal where attention may turn next—from capital planning to product advancement.

Beam’s stock (BEAM) trades on the Nasdaq Global Select Market. The company is headquartered in Cambridge, Massachusetts.